SAN DIEGO--(BUSINESS WIRE)-- <\/p>\n
Illumina, Inc. (ILMN) today announced that Caris Life Sciences has selected its MiSeq sequencing system to support Caris evidence-based molecular profiling service. The MiSeq system will be deployed to enablerapid, simultaneous analysis of multiple genes from formalin-fixed, paraffin-embedded (FFPE) tumor tissues using Illuminas amplicon-based assay. <\/p>\n
Caris Life Sciences molecular profiling service offers comprehensive tumor biomarker analyses coupled with an extensive clinical literature review, which matches potential therapies to patient-specific biomarker information. Using a wide array of the most clinically relevant technologies available, this service continually evolves with the emerging science to help oncologists personalize care for cancer patients. The addition of next-generation sequencing to Caris molecular profiling service represents the next step in the natural evolution of this cutting-edge offering. <\/p>\n
We are pleased to be the selected sequencing platform for Caris Life Sciences, an unmatched leader in tumor profiling, whose molecular profiling service has been ordered for more than 40,000 patients to date, said Matt Posard, Senior Vice President and General Manager of Illuminas Translational and Consumer Genomics business. This collaboration is an excellent example of applying next-generation sequencing with the goal of improving patient outcomes. <\/p>\n
Caris Life Sciences is one of the few entities to offer next-generation sequencing commercially in their CLIA-accredited laboratory, and will replace its current sequencing technology with Illuminas MiSeq system. The addition of next-generation sequencing via the MiSeq complements the variety of highly integrated technology platforms already employed by Caris, including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR). Caris molecular profiling service uses these cutting-edge technologies to comprehensively interrogate the entire cancer biological process including DNA, RNA, and protein analysis. <\/p>\n
Caris leverages the most clinically relevant technologies and biomarkers to help physicians individualize care. When we choose to add a new technology to our portfolio, we are committed to selecting a best-in-class platform and partner, as evidenced by our selection of Illumina, said Tom Spalding, Senior Vice President, Group Head Oncology and Chief Marketing Officer at Caris Life Sciences. After a thorough evaluation of top NGS platforms, Illuminas data quality, simple workflow, and commitment to a collaborative approach were key to our decision to work with them. <\/p>\n
About Illumina <\/p>\n
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. <\/p>\n
About Caris Life Sciences <\/p>\n
Caris Life Sciences is a leading biosciences company focused on developing and delivering innovative molecular diagnostic, prognostic, and theranostic services. The companys evidence-based molecular profiling service matches molecular data generated from a patients tumor with biomarker\/drug associations derived from the worlds leading clinical cancer literature. This service uses the most advanced and clinically relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of blood tests based on the companys proprietary Carisome platform a proprietary, blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Through the precise and personalized information provided by technologies like molecular profiling and Carisome, the company believes that the quality of healthcare can be dramatically improved, while also significantly reducing costs. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe, and other international markets. To learn more, please visit http:\/\/www.carislifesciences.com<\/a>. <\/p>\n<\/p>\n More here:<\/p>\n Caris Life Sciences Selects Illumina\u2019s MiSeq\u00ae System to Enable Next-Generation Sequencing as Part of its Molecular ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (ILMN) today announced that Caris Life Sciences has selected its MiSeq sequencing system to support Caris evidence-based molecular profiling service. Continue reading